Background. In the field of Alzheimer's disease (AD), the validation of biomarkers for early AD diagnosis and for use as a surrogate outcome in AD clinical trials is of considerable research interest. Objective. To characterize the clinical profile and genetic, neuroimaging and neurophysiological biomarkers of prodromal AD in amnestic mild cognitive impairment (aMCI) patients enrolled in the IMI WP5 PharmaCog (also referred to as the European ADNI study). Methods. A total of 147 aMCI patients were enrolled in 13 European memory clinics. Patients underwent clinical and neuropsychological evaluation, magnetic resonance imaging (MRI), electroencephalography (EEG) and lumbar puncture to assess the levels of amyloid beta peptide 1-42 (A beta 42), tau and p-tau, and blood samples were collected. Genetic (APOE), neuroimaging (3T morphometry and diffusion MRI) and EEG (with resting-state and auditory oddball event-related potential (AO-ERP) paradigm) biomarkers were evaluated. Results. Prodromal AD was found in 55 aMCI patients defined by low A beta 42 in the cerebrospinal fluid (A beta positive). Compared to the aMCI group with high A beta 42 levels (A beta negative), A beta positive patients showed poorer visual (P = 0.001), spatial recognition (P < 0.0005) and working (P = 0.024) memory, as well as a higher frequency of APOE4 (P < 0.0005), lower hippocampal volume (P = 0.04), reduced thickness of the parietal cortex (P < 0.009) and structural connectivity of the corpus callosum (P < 0.05), higher amplitude of delta rhythms at rest (P = 0.03) and lower amplitude of posterior cingulate sources of AO-ERP (P = 0.03). Conclusion. These results suggest that, in aMCI patients, prodromal AD is characterized by a distinctive cognitive profile and genetic, neuroimaging and neurophysiological biomarkers. Longitudinal assessment will help to identify the role of these biomarkers in AD progression.

Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'

Jovicich, Jorge;
2016-01-01

Abstract

Background. In the field of Alzheimer's disease (AD), the validation of biomarkers for early AD diagnosis and for use as a surrogate outcome in AD clinical trials is of considerable research interest. Objective. To characterize the clinical profile and genetic, neuroimaging and neurophysiological biomarkers of prodromal AD in amnestic mild cognitive impairment (aMCI) patients enrolled in the IMI WP5 PharmaCog (also referred to as the European ADNI study). Methods. A total of 147 aMCI patients were enrolled in 13 European memory clinics. Patients underwent clinical and neuropsychological evaluation, magnetic resonance imaging (MRI), electroencephalography (EEG) and lumbar puncture to assess the levels of amyloid beta peptide 1-42 (A beta 42), tau and p-tau, and blood samples were collected. Genetic (APOE), neuroimaging (3T morphometry and diffusion MRI) and EEG (with resting-state and auditory oddball event-related potential (AO-ERP) paradigm) biomarkers were evaluated. Results. Prodromal AD was found in 55 aMCI patients defined by low A beta 42 in the cerebrospinal fluid (A beta positive). Compared to the aMCI group with high A beta 42 levels (A beta negative), A beta positive patients showed poorer visual (P = 0.001), spatial recognition (P < 0.0005) and working (P = 0.024) memory, as well as a higher frequency of APOE4 (P < 0.0005), lower hippocampal volume (P = 0.04), reduced thickness of the parietal cortex (P < 0.009) and structural connectivity of the corpus callosum (P < 0.05), higher amplitude of delta rhythms at rest (P = 0.03) and lower amplitude of posterior cingulate sources of AO-ERP (P = 0.03). Conclusion. These results suggest that, in aMCI patients, prodromal AD is characterized by a distinctive cognitive profile and genetic, neuroimaging and neurophysiological biomarkers. Longitudinal assessment will help to identify the role of these biomarkers in AD progression.
2016
6
Galluzzi, S; Marizzoni, M; Babiloni, C; Albani, D; Antelmi, L; Bagnoli, C; Bartres Faz, D; Cordone, S; Didic, M; Farotti, L; Fiedler, U; Forloni, G; Girtler, N; Hensch, T; Jovicich, Jorge; Leeuwis, A; Marra, C; Molinuevo, J. L; Nobili, F; Pariente, J; Parnetti, L; Payoux, P; Del Percio, C; Ranjeva, J. P; Rolandi, E; Rossini, P. M; Schönknecht, P; Soricelli, A; Tsolaki, M; Visser, P. J; Wiltfang, J; Richardson, J. C; Bordet, R; Blin, O; Frisoni, G. B.
File in questo prodotto:
File Dimensione Formato  
Galluzzi et al., J Int Med 2016, Clinical and biomarker profiling of prodromal AD in IMI Pharmacog's WP5 - a European ADNI study.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 699.48 kB
Formato Adobe PDF
699.48 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/179308
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 53
social impact